SCHEMBL18436805

SCHEMBL18436805

Cc1ccc(N2CC(C)N(C(=O)c3ccccn3)C(C)C2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.50
HSD11B1 P28845 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CHRNB2 P17787 1/20 0.44
CHRNB4 P30926 1/20 0.44
CHRNA3 P32297 1/20 0.44
CHRNA7 P36544 1/20 0.44
CHRNA4 P43681 1/20 0.44
RBP4 P02753 1/20 0.42
MAPT P10636 2/20 0.41
NPC1 O15118 2/20 0.41
PKM P14618 2/20 0.41
RAB9A P51151 2/20 0.41
KDM4E B2RXH2 1/20 0.41
HTT P42858 1/20 0.41
KLF5 Q13887 1/20 0.41
PDE10A Q9Y233 2/20 0.41
GAA P10253 1/20 0.41
PTGS2 P35354 1/20 0.40
ALDH1A1 P00352 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19012370 1.00 SMN1; SMN2 (0.50) SMN1; SMN2HSD11B1L3MBTL1CHRNB2CHRNB4
SCHEMBL18436657 0.89 HSD11B1 (0.45) SMN1; SMN2HSD11B1L3MBTL1CHRNB2CHRNB4
SCHEMBL19012534 0.86 HSD11B1 (0.46) SMN1; SMN2HSD11B1L3MBTL1CHRNB2CHRNB4
SCHEMBL19001032 0.86 PLA2G1B (0.51) SMN1; SMN2HSD11B1L3MBTL1CHRNB2CHRNB4
SCHEMBL18436815 0.86 CSF1R (0.46) SMN1; SMN2HSD11B1L3MBTL1CHRNB2CHRNB4
SCHEMBL19012742 0.86 HSD11B1 (0.46) SMN1; SMN2HSD11B1L3MBTL1CHRNB2CHRNB4
SCHEMBL19001092 0.86 PLA2G1B (0.51) SMN1; SMN2HSD11B1L3MBTL1CHRNB2CHRNB4
SCHEMBL19012397 0.80 SMO (0.46) SMN1; SMN2HSD11B1NPC1RAB9AHTT
SCHEMBL19012460 0.80 SMO (0.46) SMN1; SMN2HSD11B1NPC1RAB9AHTT
SCHEMBL18436771 0.80 SMO (0.46) SMN1; SMN2HSD11B1NPC1RAB9AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3124482-B1 QUINOLINE DERIVATIVES AS SMO INHIBITORS GUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD (CN) 2019-09-11 EP disclosed
US-20170174703-A1 QUINOLINE DERIVATIVES AS SMO INHIBITORS GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2017-06-22 US disclosed
EP-3124482-A1 QUINOLINE DERIVATIVES AS SMO INHIBITORS GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2017-02-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170174703-A1 QUINOLINE DERIVATIVES AS SMO INHIBITORS SMO, GLI1, SHH SMN1; SMN2 4029/4885HSD11B1 3620/4885L3MBTL1 2398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.